Snapwell Shipping Container for Live Cell Cultures
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a novel shipping container designed to protect live cell cultures during transport.
Targeted Disruption of Rpe65 Gene for Retinal Disease Research
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a targeted disruption of the Rpe65 gene in mice, a novel model for studying retinal diseases and testing potential therapies.
Detection of Organomercurial Compound Biosynthesis in Microbial Communities
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative detection methods for organomercurial biosynthesis in microbial communities.
RPGR Gene Therapy for Retinitis Pigmentosa
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of RPGR gene therapy for Retinitis Pigmentosa.
Biodegradable Tissue Scaffold for Multi-Tissue Transplantation
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a biodegradable tissue scaffold designed for multi-tissue transplantation.
A Robust Method to Generate Macular vs Peripheral RPE Cells for Cell Therapy and Drug Discovery
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a robust method to generate macular and peripheral retinal pigment epithelium (RPE) cells for targeted therapies and drug discovery.
Mini-Bioreactor for Enhanced Organoid Culture
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a mini-bioreactor designed to enhance organoid culture outcomes.
Myocilin Mutant Cell Lines for Glaucoma Research and Drug Screening
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of innovative therapeutic strategies targeting myocilin mutations in glaucoma.
Immunosuppressive Exosomes for Treating Autoimmune Diseases
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of immunosuppressive exosomes derived from IL-35 and IL-27 producing Bregs as a therapeutic treatment for autoimmune diseases.
Stable Cell Line for Large Scale Production of Human Retinoschisin for Ocular Therapy
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for the development of a stable cell line for the production of human Retinoschisin (RS1) for therapeutic applications in ocular diseases.